Associate Director, Clinical Operations

Marea Therapeutics is a clinical-stage biotechnology company based in South San Francisco with a growing pipeline of first-in-class therapies to address genetically validated cardioendocrine disease targets. Our therapies have the potential to serve as transformative treatment options for significant patient populations living with cardioendocrine diseases.

The company’s lead program, MAR
001, is being developed for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels and elevated risk of acute pancreatitis. Preclinical models with MAR
001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity. MAR
001 has demonstrated strong and a differentiated profile in patients and is approaching Phase 3 development. Our second clinical asset, MAR
002, is a monoclonal antibody targeting excess growth hormone produced by the pituitary gland in the rare hormonal disorder, acromegaly. MAR
002 has potential to become best‑in‑disease and is quickly progressing into Phase 2/3 clinical development. We also have a third asset that is swiftly advancing through research discovery, with DC nomination expected this year.

At Marea, we believe in the power of collaboration and the importance of leading by example. We are a tight‑knit team that values the contributions of every member, from interns to senior leaders. Our environment is dynamic, with each day presenting new challenges and opportunities for growth. Every role is “Hands‑On”, and the successful candidate will be able to work alongside team members, regardless of level, to understand challenges and drive results.

The Associate Director, Clinical Operations will provide leadership and operational oversight of Clinical Operations activities to execute clinical studies in a manner that ensures milestones and company goals are met, and costs maintained within budget. This role will have program‑level accountability for timeline, budget, quality, risk management, and ensuring compliance with Good Clinical Practice (GCP)

The position will work in a cross‑functional environment with representatives from other involved functions and will oversee the activities of Clinical Research Organizations (CROs) and other vendors in the conduct and management of clinical studies. The successful candidate may eventually mentor junior staff in the set‑up, maintenance, and close‑out of clinical trials.

In this role, the Associate Director will be a key clinical operations leader supporting our MAR
001 program. MAR
001 is a monoclonal antibody aiming to be the first biologic with a clean metabolic profile for the treatment of sHTG. MAR
001 has the potential to become best‑in‑disease and is rapidly progressing from phase 2 to phase 3 clinical development. This Associate Director position will be expected to drive execution across study start‑up, vendor oversight, and delivery of high‑quality late phase clinical data in a lipid disorders setting.

This is a full‑time, South San Francisco‑based position with the expectation of working on‑site at least three days per week.

• Support program lead with setting and timely executing the development strategies for the clinical studies.
• Responsible for the strategic and operational oversight, management, execution, and delivery of the clinical studies for MAR
  001 and related clinical program activities.
• Lead the Study Management Team (SMT) for assigned clinical study.
• Resolve and/or elevate issues raised by the clinical operations team or the SMT.
• Ensure consistency between studies for assigned clinical program.
• Support vendor selection, including request for proposals, leading bid defense meetings, critical review of contracts and negotiation of work orders.
• Oversee CROs and other selected vendors on a product level including setting and monitoring key performance indicators and ensuring successful execution of the clinical program/studies and may co‑lead operational governance meetings.
• Act as the main escalation point of contact for strategic CRO partner(s) for the assigned study and for the key stakeholders…